CJC-1295 research guide for Quatis. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Unlike common nutraceuticals stocked in every health store, CJC-1295 moves through a dedicated online market that Quatis residents access almost entirely online. What this means for Quatis researchers is that geography is secondary to your ability to assess COA data — and those verification methods are available to every researcher. A credible CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. What follows is a practical research guide built specifically around CJC-1295, covering everything a Quatis researcher needs before placing a first order.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Quatis comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Community reputation in research forums is a valuable complement to COA verification — vendors with multi-year positive track records have earned that standing through repeat quality delivery. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Quatis
COA-verified · International tracking · Research grade
All use of CJC-1295 in Quatis or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should follow research laboratory protocols. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no cost saving makes omitting this acceptable. Protocol documentation — recording exactly what was used, when, and how — is a research best practice for CJC-1295 that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
